News

Mitsubishi UFJ Financial Group Weighs in on Medpace Holdings Inc’s FY2018 Earnings (MEDP)

Medpace Holdings Inc (NASDAQ:MEDP) – Equities researchers at Mitsubishi UFJ Financial Group raised their FY2018 earnings per share estimates for Medpace in a report issued on Thursday, November 8th, according to Zacks Investment Research. Mitsubishi UFJ Financial Group analyst J. Twizell now anticipates that the company will post earnings of $2.56 per share for the year, up from their prior estimate of $2.48. Mitsubishi UFJ Financial Group also issued estimates for Medpace’s Q4 2018 earnings at $0.73 EPS, Q2 2019 earnings at $0.74 EPS, Q4 2019 earnings at $0.80 EPS, FY2019 earnings at $2.96 EPS and FY2020 earnings at $3.38 EPS.

Medpace (NASDAQ:MEDP) last issued its earnings results on Thursday, November 1st. The company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.04. Medpace had a net margin of 10.84% and a return on equity of 15.86%. The firm had revenue of $179.00 million for the quarter, compared to analyst estimates of $175.07 million. During the same quarter last year, the business posted $0.40 earnings per share. The company’s quarterly revenue was up 44.4% on a year-over-year basis.

A number of other analysts have also weighed in on the stock. BidaskClub upgraded shares of Medpace from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 12th. SunTrust Banks upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $63.00 target price on the stock in a research report on Wednesday, October 31st. They noted that the move was a valuation call. TheStreet upgraded shares of Medpace from a “c” rating to a “b-” rating in a research report on Friday, August 10th. Finally, Zacks Investment Research upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a report on Thursday, November 1st. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $44.43.

READ  Mitsubishi UFJ Financial Group (MUFG) Receives “Hold” Rating from Zacks Investment Research

Medpace stock traded down $2.58 during mid-day trading on Monday, reaching $61.40. The company had a trading volume of 770,066 shares, compared to its average volume of 525,805. Medpace has a fifty-two week low of $31.75 and a fifty-two week high of $65.09. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.66 and a quick ratio of 0.66. The firm has a market capitalization of $2.20 billion, a P/E ratio of 40.39, a P/E/G ratio of 1.59 and a beta of 1.49.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC bought a new position in Medpace during the second quarter worth $107,000. Metropolitan Life Insurance Co. NY raised its stake in Medpace by 57.1% during the second quarter. Metropolitan Life Insurance Co. NY now owns 4,144 shares of the company’s stock worth $178,000 after buying an additional 1,507 shares during the last quarter. Sei Investments Co. raised its stake in Medpace by 5,087.5% during the second quarter. Sei Investments Co. now owns 4,565 shares of the company’s stock worth $196,000 after buying an additional 4,477 shares during the last quarter. Great West Life Assurance Co. Can raised its stake in Medpace by 270.1% during the third quarter. Great West Life Assurance Co. Can now owns 3,331 shares of the company’s stock worth $200,000 after buying an additional 2,431 shares during the last quarter. Finally, Legal & General Group Plc raised its stake in Medpace by 78.6% during the third quarter. Legal & General Group Plc now owns 3,436 shares of the company’s stock worth $206,000 after buying an additional 1,512 shares during the last quarter. 67.54% of the stock is owned by institutional investors and hedge funds.

READ  Arrest Of Nissan Chairman Threatens Future Of Alliance With Mitsubishi And Renault : NPR

In other news, major shareholder Medpace Investors, Llc sold 61,141 shares of Medpace stock in a transaction on Wednesday, September 19th. The shares were sold at an average price of $60.20, for a total transaction of $3,680,688.20. Following the transaction, the insider now owns 9,084,369 shares in the company, valued at $546,879,013.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 46,778 shares of Medpace stock in a transaction on Thursday, September 27th. The stock was sold at an average price of $58.96, for a total transaction of $2,758,030.88. Following the transaction, the chief executive officer now directly owns 351,851 shares of the company’s stock, valued at approximately $20,745,134.96. The disclosure for this sale can be found here. In the last quarter, insiders have sold 396,559 shares of company stock worth $23,422,389. 29.50% of the stock is owned by company insiders.

About Medpace

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Recommended Story: Systematic Risk and Investors

Get a free copy of the Zacks research report on Medpace (MEDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Medpace and related companies with MarketBeat.com’s FREE daily email newsletter.

READ  Josh Pickering and Brodie Nolan take out 2018 Cessnock Mitsubishi Australian Postie Bike Grand Prix

Source link